-
Mashup Score: 0
Jeff P. Sharman, MD, discusses unmet needs, prognosis, and innovative treatments like pirtobrutinib in the evolving landscape of chronic lymphocytic leukemia.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
Kapila Viges, MD, and John Mascarenhas, MD, discuss the role of surrogate end points in multiple myeloma clinical trials.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0KOMET-001 Phase II Trial Results Encouraging for Ziftomenib Monotherapy in NPM1-Mutant AML | Blood Cancers Today - 2 day(s) ago
A new study protocol plans for two phase III trials to evaluate the agent in intensive and nonintensive combinations for AML.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Video Insights | Blood Cancers Today - 3 day(s) ago
Watch expert interviews from leading hematologists and oncologists on Blood Cancers Today.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8Linvoseltamab Now Under FDA Review as a Potential Treatment Option for RRMM | Blood Cancers Today - 3 day(s) ago
The FDA has accepted a BLA for linvoseltamab for the treatment of adult patients with relapsed or refractory multiple myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
The FDA has accepted a BLA for linvoseltamab for R/R myeloma in the fourth-line setting or for patients who are in the third-line setting and are refractory to the last line of therapy. Read more about the approval, with insight from @JoshuaRichterMD. ➡️ https://t.co/Ft05VJvb7W https://t.co/iA7Qu4ZbOt
-
-
Mashup Score: 11Natalie Callander, MD, on Selinexor in Myeloma: Triplet Combinations, Dosing, Efficacy | Blood Cancers Today - 3 day(s) ago
Natalie Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Olutasidenib and Azacitidine Combination Expands Options for mIDH1 Relapsed or Refractory AML | Blood Cancers Today - 4 day(s) ago
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant AML treated with combination of olutasidenib plus azacitidine in multiple studies.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2TREATT Trial Evaluates Tranexamic Acid for Bleeding Prevention in Hematologic Malignancies | Blood Cancers Today - 4 day(s) ago
Compared with placebo, tranexamic acid did not reduce bleeding in patients with hematologic malignancies and severe thrombocytopenia undergoing intensive chemotherapy.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8Optimizing MDS Management: Key Takeaways from the COMMANDS Trial | Blood Cancers Today - 4 day(s) ago
Thomas LeBlanc, MD, MA; Andrew Brunner, MD; and Jamie Koprivnikar, MD, discuss the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
The positive opinion is based on results from the phase II TRANSCEND FL study, in which liso-cel showed an ORR of 97.1% and a CR rate of 94.2%.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet
🙌 We recently spoke with @jeff_sharman, of @TheUSONetwork, who discussed the evolving treatment landscape for #CLL, unmet needs in CLL management, and the current prognosis for CLL patients. 📺 Watch here! https://t.co/cilyVCllmu https://t.co/ZlQEI8uoQF